(Q28171385)

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961392-0

7 January 2021

Differential metabolism of arachidonic acid in nasal polyp epithelial cells cultured from aspirin-sensitive and aspirin-tolerant patients

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961392-0

7 January 2021

Inhibition by prostaglandins of leukotriene B4 release from activated neutrophils

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961392-0

7 January 2021

Prostaglandins inhibit inflammatory mediator release from rat mast cells

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961392-0

7 January 2021

Enhancement of acute allergic inflammation by indomethacin is reversed by prostaglandin E2: apparent correlation with in vivo modulation of mediator release

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961392-0

7 January 2021

Prostaglandin E2 prevents diclofenac-induced enhancement of histamine release and inflammation evoked by in vivo challenge with compound 48/80 in the hamster cheek pouch

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961392-0

7 January 2021

An intravital microscopic model for mast cell-dependent inflammation in the hamster cheek pouch

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961392-0

7 January 2021

Prostaglandin modulation of mast cell-dependent inflammation

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961392-0

7 January 2021

Protective and bronchodilator effects of prostaglandin E and salbutamol in aspirin-induced asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961392-0

7 January 2021

Inhaled PGE2 prevents aspirin-induced bronchoconstriction and urinary LTE4 excretion in aspirin-sensitive asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961392-0

7 January 2021

Enhanced expression of cyclo-oxygenase isoenzyme 2 (COX-2) in asthmatic airways and its cellular distribution in aspirin-sensitive asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961392-0

7 January 2021

Classification of allergic and pseudoallergic reactions to drugs that inhibit cyclooxygenase enzymes

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961392-0

7 January 2021

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961392-0

1 reference

7 January 2021

Tolerability of meloxicam in patients with histories of adverse reactions to nonsteroidal anti-inflammatory drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961392-0

7 January 2021

The use of nimesulide in patients with acetylsalicylic acid and nonsteroidal anti-inflammatory drug intolerance

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961392-0

7 January 2021

Nimesulide in the treatment of patients intolerant of aspirin and other NSAIDs

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961392-0

7 January 2021

Long-term tolerability of nimesulide and acetaminophen in nonsteroidal antiinflammatory drug-intolerant patients

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961392-0

7 January 2021

Safety of COX-2 Inhibitors in Asthma Patients with Aspirin Hypersensitivity

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961392-0

7 January 2021

Biochemical and clinical evidence that aspirin-intolerant asthmatic subjects tolerate the cyclooxygenase 2-selective analgetic drug celecoxib

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961392-0

7 January 2021

Safety of a cyclooxygenase-2 inhibitor in patients with aspirin-sensitive asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961392-0

7 January 2021

Successful use of cyclooxygenase-2 inhibitor in a patient with aspirin-induced asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961392-0

7 January 2021

Tolerability of rofecoxib in patients with adverse reactions to nonsteroidal anti-inflammatory drugs: a study of 216 patients and literature review.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961392-0

7 January 2021

NSAID-sensitive patients tolerate rofecoxib

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961392-0

7 January 2021

Lack of cross-reactivity between rofecoxib and aspirin in aspirin-sensitive patients with asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961392-0

7 January 2021

Safety of a specific COX-2 inhibitor in aspirin-induced asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961392-0

7 January 2021

The safety of celecoxib in patients with aspirin-sensitive asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961392-0

7 January 2021

Celecoxib in patients with asthma and aspirin intolerance. The Celecoxib in Aspirin-Intolerant Asthma Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961392-0

7 January 2021

Effect of the cyclooxygenase-2 inhibitor celecoxib on bronchial responsiveness and cough reflex sensitivity in asthmatics

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961392-0

7 January 2021

Lack of effect of the 5-lipoxygenase inhibitor zileuton in blocking oral aspirin challenges in aspirin-sensitive asthmatics

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961392-0

7 January 2021

Inhibition of idiosyncratic reactions to aspirin in asthmatic patients by clemastine

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961392-0

7 January 2021

Urticaria and angioedema induced by COX-2 inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961392-0

7 January 2021

Anaphylactoid reaction to a cyclooxygenase-2 inhibitor in a patient who had a reaction to a cyclooxygenase-1 inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961392-0

7 January 2021

Tolerability to new COX-2 inhibitors in NSAID-sensitive patients with cutaneous reactions

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961392-0

7 January 2021